drugset / Trial / NCT02286635

Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort

NCT02286635

Phase 1 Completed 58 enrolled PTC Therapeutics
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of the study is to determine the potential effects of multiple doses of rifampin and clarithromycin on the single dose pharmacokinetics (PK) of the deflazacort active metabolite (21 desacetyl-DFZ) in healthy adult subjects.

Timeline

Start
2014-11
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Clarithromycin Small molecule 500 mg Oral
Subject Deflazacort Other / unclassified 18 mg Oral
Subject Rifampin Small molecule 600 mg Oral

Indications

No indication recorded.